When to screen and not to screen

Colorectal cancer (CRC) is the third most common cause of cancer-related deaths with treatment of advanced and metastatic CRC (mCRC) remaining palliative at best.(1) The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target for a multitude of malignancies, including mCR...

Descripción completa

Detalles Bibliográficos
Autor principal: Cruickshanks, Nichola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115864/
https://www.ncbi.nlm.nih.gov/pubmed/24424112
http://dx.doi.org/10.4161/cbt.27741
_version_ 1782468586987585536
author Cruickshanks, Nichola
author_facet Cruickshanks, Nichola
author_sort Cruickshanks, Nichola
collection PubMed
description Colorectal cancer (CRC) is the third most common cause of cancer-related deaths with treatment of advanced and metastatic CRC (mCRC) remaining palliative at best.(1) The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target for a multitude of malignancies, including mCRC. Ligand-binding to EGFR results in the subsequent activation of multiple signal transduction pathways including the PI3K/AKT and RAS/RAF/MAPK pathways, which are vital for cell growth and survival.(2) Constitutive activation of these signaling pathways leads to deregulated cellular proliferation, malignant progression, and invasion.(3)
format Online
Article
Text
id pubmed-5115864
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-51158642016-11-29 When to screen and not to screen Cruickshanks, Nichola Cancer Biol Ther Commentary Colorectal cancer (CRC) is the third most common cause of cancer-related deaths with treatment of advanced and metastatic CRC (mCRC) remaining palliative at best.(1) The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target for a multitude of malignancies, including mCRC. Ligand-binding to EGFR results in the subsequent activation of multiple signal transduction pathways including the PI3K/AKT and RAS/RAF/MAPK pathways, which are vital for cell growth and survival.(2) Constitutive activation of these signaling pathways leads to deregulated cellular proliferation, malignant progression, and invasion.(3) Taylor & Francis 2014-01-14 /pmc/articles/PMC5115864/ /pubmed/24424112 http://dx.doi.org/10.4161/cbt.27741 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Commentary
Cruickshanks, Nichola
When to screen and not to screen
title When to screen and not to screen
title_full When to screen and not to screen
title_fullStr When to screen and not to screen
title_full_unstemmed When to screen and not to screen
title_short When to screen and not to screen
title_sort when to screen and not to screen
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115864/
https://www.ncbi.nlm.nih.gov/pubmed/24424112
http://dx.doi.org/10.4161/cbt.27741
work_keys_str_mv AT cruickshanksnichola whentoscreenandnottoscreen

Ejemplares similares